Colchicine is an effective therapeutic agent in erosive hand osteoarthritis: Colchicine and erosive hand osteoarthritis

Adem  Ertürk; Alper Sarı

doi:10.28982/josam.7857

Authors

Adem Ertürk Division of Rheumatology, Department of Internal Medicine, Afyonkarahisar Health Sciences University Faculty of Medicine, Afyonkarahisar, Turkey https://orcid.org/0000-0001-8882-0692
Alper Sarı Department of Internal Medicine, Afyonkarahisar Health Sciences University Faculty of Medicine, Afyonkarahisar, Turkey https://orcid.org/0000-0002-4327-8032

DOI:

https://doi.org/10.28982/josam.7857

Keywords:

erosive hand osteoarthritis, colchicine, Australian Canadian Osteoarthritis Hand Index, visual analog scale, erythrocyte sedimentation rate, C-reactive protein

Abstract

Background/Aim: The efficacy of colchicine has been assessed in hand osteoarthritis; however, no studies have investigated its use in the more severe subtype of hand osteoarthritis, known as erosive hand osteoarthritis (EHOA). This retrospective cohort study investigated whether colchicine therapy could provide symptomatic relief and improve inflammation markers in patients with EHOA.

Methods: The study included a total of 43 EHOA patients using colchicine (2×0.5 mg) + paracetamol (3×500 mg) daily (colchicine group) and 43 EHOA patients using only paracetamol (3×500 mg) (standard therapy group). Both groups were evaluated for various parameters.

Results: The groups were similar in terms of age, sex distribution, and other sociodemographic variables. The decreases in erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels from baseline were significantly greater in the colchicine group (P<0.001). Additionally, the visual analog scale (VAS) and Australian Canadian Osteoarthritis Hand Index (AUSCAN) scores, which include pain, stiffness, function, and total score, were significantly better in the colchicine group at 3 months compared to the standard therapy group (P<0.001). Furthermore, although both groups showed significant improvements in these parameters, the amount of improvement was significantly greater in the colchicine group (P<0.001).

Conclusion: The combined use of colchicine and paracetamol improved CRP and ESR levels, VAS score, and all AUSCAN scores in patients with EHOA. Moreover, these benefits were significantly greater than standard therapy with paracetamol alone. Colchicine appears to be an effective therapeutic agent in the treatment of EHOA.

Downloads

Download data is not yet available.

References

Vilá S. Inflammation in Osteoarthritis. P R Health Sci J. 2017;36:123–9.

Davis CR, Ruediger CD, Dyer KA, Lester S, Graf SW, Kroon FPB, et al. Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH). Osteoarthritis Cartilage. 2021;29:208–14. DOI: https://doi.org/10.1016/j.joca.2020.11.002

Favero M, Belluzzi E, Ortolan A, Lorenzin M, Oliviero F, Doria A, et al. Erosive hand osteoarthritis: latest findings and outlook. Nat Rev Rheumatol. 2022;18:171–83. DOI: https://doi.org/10.1038/s41584-021-00747-3

McAlindon TE, Driban JB, Roberts MB, Duryea J, Haugen IK, Schaefer LF, et al. Erosive Hand Osteoarthritis: Incidence and Predictive Characteristics Among Participants in the Osteoarthritis Initiative. Arthritis & Rheumatology. 2021;73:2015–24. DOI: https://doi.org/10.1002/art.41757

Kazmers NH, Meeks HD, Novak KA, Yu Z, Fulde GL, Thomas JL, et al. Familial Clustering of Erosive Hand Osteoarthritis in a Large Statewide Cohort. Arthritis & Rheumatology. 2021;73:440–7. DOI: https://doi.org/10.1002/art.41520

Kwok WY, Kloppenburg M, Rosendaal FR, van Meurs JB, Hofman A, Bierma-Zeinstra SMA. Erosive hand osteoarthritis: its prevalence and clinical impact in the general population and symptomatic hand osteoarthritis. Ann Rheum Dis. 2011;70:1238–42. DOI: https://doi.org/10.1136/ard.2010.143016

Tenti S, Ferretti F, Gusinu R, Gallo I, Giannotti S, Pozza A, et al. Impact of thumb osteoarthritis on pain, function, and quality of life: a comparative study between erosive and non-erosive hand osteoarthritis. Clin Rheumatol. 2020;39:2195–206. DOI: https://doi.org/10.1007/s10067-020-04982-z

Acheson RM, Collart AB. New Haven survey of joint diseases. XVII. Relationship between some systemic characteristics and osteoarthrosis in a general population. Ann Rheum Dis. 1975;34:379–87. DOI: https://doi.org/10.1136/ard.34.5.379

Y. Sun HBSSK. Serum uric acid and patterns of radiographic osteoarthritis - the Ulm Osteoarthritis Study. Scand J Rheumatol. 2000;29:380–6. DOI: https://doi.org/10.1080/030097400447589

Muehleman C, Li J, Aigner T, Rappoport L, Mattson E, Hirschmugl C, et al. Association between crystals and cartilage degeneration in the ankle. J Rheumatol. 2008;35:1108–17.

Leung YY, Yao Hui LL, Kraus VB. Colchicine—Update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341–50. DOI: https://doi.org/10.1016/j.semarthrit.2015.06.013

Aran S, Malekzadeh S, Seifirad S. A double-blind randomized controlled trial appraising the symptom-modifying effects of colchicine on osteoarthritis of the knee. Clin Exp Rheumatol. 2011;29:513–8.

Restrepo-Escobar M, Carmona-Franceschi M de J, Donado Gómez JH. Revisión sistemática de la literatura sobre el tratamiento con colchicina en pacientes adultos con osteoartritis de rodilla. Revista Colombiana de Reumatología. 2017;24:102–11. DOI: https://doi.org/10.1016/j.rcreu.2017.01.002

Leung YY, Haaland B, Huebner JL, Wong SBS, Tjai M, Wang C, et al. Colchicine lack of effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): a randomized controlled trial. Osteoarthritis Cartilage. 2018;26:631–40. DOI: https://doi.org/10.1016/j.joca.2018.01.026

Cioroianu GO, Florescu A, Mușetescu AE, Sas TN, Rogoveanu OC. Colchicine versus Physical Therapy in Knee Osteoarthritis. Life. 2022;12:1297. DOI: https://doi.org/10.3390/life12091297

Døssing A, Henriksen M, Ellegaard K, Nielsen SM, Stamp LK, Müller FC, et al. Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2023;5:e254–62. DOI: https://doi.org/10.1016/S2665-9913(23)00065-6

Altman R, Alarcon G, Appelrouth D, Bloch D, Borenstein D, Brandt K, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis Rheum. 1990;33:1601–10. DOI: https://doi.org/10.1002/art.1780331101

Kedor C, Detert J, Rau R, Wassenberg S, Listing J, Klaus P, et al. Hydroxychloroquine in patients with inflammatory and erosive osteoarthritis of the hands: results of the OA-TREAT study—a randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. RMD Open. 2021;7:e001660. DOI: https://doi.org/10.1136/rmdopen-2021-001660

Liu B, Wang J, Li Y, Li K, Zhang Q. The association between systemic immune-inflammation index and rheumatoid arthritis: evidence from NHANES 1999–2018. Arthritis Res Ther. 2023;25:34. DOI: https://doi.org/10.1186/s13075-023-03018-6

Lee LE, Ahn SS, Pyo JY, Song JJ, Park Y-B, Lee S-W. Pan-immune-inflammation value at diagnosis independently predicts all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol. 2021;39:88–93. DOI: https://doi.org/10.55563/clinexprheumatol/m46d0v

Bellamy N, Campbell J, Haraoui B, Buchbinder R, Hobby K, Roth JH, et al. Dimensionality and clinical importance of pain and disability in hand osteoarthritis: Development of the Australian/Canadian (AUSCAN) Osteoarthritis Hand Index. Osteoarthritis Cartilage. 2002;10:855–62. DOI: https://doi.org/10.1053/joca.2002.0837

Richette P, Latourte A, Sellam J, Wendling D, Piperno M, Goupille P, et al. Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial. Ann Rheum Dis. 2021;80:349–55. DOI: https://doi.org/10.1136/annrheumdis-2020-218547

Plotz B, Pillinger M, Samuels J. Colchicine and clinical trials for hand osteoarthritis. Osteoarthritis Cartilage. 2022;30:172–3. DOI: https://doi.org/10.1016/j.joca.2020.12.026

Das SK, Ramakrishnan S, Mishra K, Srivastava R, Agarwal GG, Singh R, et al. A randomized controlled trial to evaluate the slow-acting symptom-modifying effects of colchicine in osteoarthritis of the knee: A preliminary report. Arthritis Rheum. 2002;47:280–4. DOI: https://doi.org/10.1002/art.10455

Das SK, Mishra K, Ramakrishnan S, Srivastava R, Agarwal GG, Singh R, et al. A randomized controlled trial to evaluate the slow-acting symptom modifying effects of a regimen containing colchicine in a subset of patients with osteoarthritis of the knee. Osteoarthritis Cartilage. 2002;10:247–52. DOI: https://doi.org/10.1053/joca.2002.0516

Amirpour A. The effect of colchicine in improving the symptoms of patients with knee osteoarthritis. J Babol Univ Med Sci. 2016;18(11):7-13.

Marpaung B, Siregar J. Effect of Sidaguri ( Sidarhombifolia L ) on C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) in osteoarthritis patients. IOP Conf Ser Earth Environ Sci. 2018;125:012188. DOI: https://doi.org/10.1088/1755-1315/125/1/012188

Pepys MB, Hirschfield GM. C-reactive protein: a critical update. Journal of Clinical Investigation. 2003;111:1805–12. DOI: https://doi.org/10.1172/JCI200318921

Yalcinkaya R, Öz FN, Durmuş SY, Fettah A, Kaman A, Teke TA, et al. Is There a Role for Laboratory Parameters in Predicting Coronary Artery Involvement in Kawasaki Disease? Klin Padiatr. 2022;234:382–7. DOI: https://doi.org/10.1055/a-1816-6754

Oztas Y, Yalcinkaya A. Oxidative alterations in sickle cell disease: Possible involvement in disease pathogenesis. World Journal of Hematology. 2017;6:55. DOI: https://doi.org/10.5315/wjh.v6.i3.55

Tishkowski K, Gupta V. Erythrocyte Sedimentation Rate. 2023.

Marshall M, Watt FE, Vincent TL, Dziedzic K. Hand osteoarthritis: clinical phenotypes, molecular mechanisms and disease management. Nat Rev Rheumatol. 2018;14:641–56. DOI: https://doi.org/10.1038/s41584-018-0095-4

Meltem CM, Bayram U, Engin C. Methodological quality of randomized controlled trials of home-based rehabilitation in knee osteoarthritis: A cross-sectional survey. J Surg Med. 2023;7(4):280-7. DOI: https://doi.org/10.28982/josam.1114280

Kingsbury SR, Tharmanathan P, Keding A, Ronaldson SJ, Grainger A, Wakefield RJ, et al. Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis. Ann Intern Med. 2018;168:385. DOI: https://doi.org/10.7326/M17-1430

Kloppenburg M, Peterfy C, Haugen IK, Kroon F, Chen S, Wang L, et al. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1α and anti-interleukin-1β dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann Rheum Dis. 2019;78:413–20. DOI: https://doi.org/10.1136/annrheumdis-2018-213336

Aitken D, Laslett LL, Pan F, Haugen IK, Otahal P, Bellamy N, et al. A randomised double-blind placebo-controlled crossover trial of Humira (adalimumab) for erosive hand Osteoarthritis – the HUMOR trial. Osteoarthritis Cartilage. 2018;26:880–7. DOI: https://doi.org/10.1016/j.joca.2018.02.899

Kloppenburg M, Ramonda R, Bobacz K, Kwok W-Y, Elewaut D, Huizinga TWJ, et al. Etanercept in patients with inflammatory hand osteoarthritis (EHOA): a multicentre, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018;77:1757–64. DOI: https://doi.org/10.1136/annrheumdis-2018-213202

Kroon FPB, Kortekaas MC, Boonen A, Böhringer S, Reijnierse M, Rosendaal FR, et al. Results of a 6-week treatment with 10 mg prednisolone in patients with hand osteoarthritis (HOPE): a double-blind, randomised, placebo-controlled trial. The Lancet. 2019;394:1993–2001. DOI: https://doi.org/10.1016/S0140-6736(19)32489-4

Grennan D, Wang S. Steroid Side Effects. JAMA. 2019;322:282. DOI: https://doi.org/10.1001/jama.2019.8506

Singh A, Molina-Garcia P, Hussain S, Paul A, Das SK, Leung Y-Y, et al. Efficacy and safety of colchicine for the treatment of osteoarthritis: a systematic review and meta-analysis of intervention trials. Clin Rheumatol. 2023;42:889–902. DOI: https://doi.org/10.1007/s10067-022-06402-w